Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of GNC-038 in relapsed or refractory non-Hodgkin lymphoma
CTR20222195Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emfizatamab in non-Hodgkin lymphoma (NHL), sponsored by Biokin Pharmaceutical. Started Oct 2022; status: active.
02
Drugs
emfizatamab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20222195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222195.